Peptide-based delivery of oligonucleotides across blood-brain barrier model

International Journal of Peptide Research and Therapeutics

Volumn 20, Issue 2, 2014, Pages 169-178

  Srimanee, Artita ^a,b   Regberg, Jakob ^b   Hallbrink, Mattias ^b   Kurrikoff, Kaido ^c   Veiman, Kadi Liis ^c   Vajragupta, Opa ^a   Langel, Ülo ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

bEnd.3; Blood brain barrier model; Cell penetrating peptide; Gene based therapy; Glioma cells; Plasmid transfection

Indexed keywords

ANGIOPEP 2; CELL PENETRATING PEPTIDE; GLIOMA HOMING PEPTIDE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CELL PROLIFERATION; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE DELIVERY SYSTEM; GENE TARGETING; GLIOMA CELL; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; TRANSCYTOSIS; ZETA POTENTIAL;

EID: 84899483274     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-013-9378-4     Document Type: Article

References (42)

1. Adenot M, Merida P, Lahana R (2007) Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery. Chemotherapy 53:73-76. doi:10.1159/000098422 (Pubitemid 46143858)
2. Bidwell GL, Perkins E, Hughes J et al (2013) Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS One 8:e55104. doi:10.1371/journal.pone. 0055104
3. Bolhassani A (2011) Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 1816:232-246. doi:10.1016/j.bbcan.2011.07.006
4. Cells E, Brown RC, Morris AP, Neil RGO (2008) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130:17-30
5. Cross D, Burmester JK (2006) Gene therapy for cancer treatment: past, present and future. Clin Med Res 4:218-227 (Pubitemid 44496015)
6. Demeule M, Currie J-C, Bertrand Y et al (2008a) Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 106:1534-1544. doi:10.1111/j.1471-4159.2008.05492.x
7. Demeule M, Re A, Che C et al (2008b) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064-1072. doi:10.1124/jpet.107.131318.Parkinson (Pubitemid 351397849)
8. Deshayes S, Morris M, Heitz F, Divita G (2008) Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 60:537-547. doi:10.1016/j.addr.2007.09.005 (Pubitemid 351222678)
9. Di L, Rong H, Feng B (2013) Demystifying brain penetration in central nervous system drug discovery. J Med Chem 56:2-12
10. Drin G, Cottin S, Blanc E et al (2003) Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278:31192-31201. doi:10.1074/jbc.M303938200 (Pubitemid 36994635)
11. Dwyer J, Hebda JK, Le Guelte A et al (2012) Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2. PLoS One 7:e45562. doi:10.1371/journal.pone.0045562
12. Eriste E, Kurrikoff K, Suhoruts J et al (2013) Peptide-based glioma-targeted drug delivery vector gHoPe2. Bioconjug Chem 24:305-313
13. Ezzat K, Zaghloul EM, EL-Andalouss S et al (2012) Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. J Control Release 162:1-8. doi:10.1016/j.jconrel. 2012.06.006
14. Gaspar VM, Correia IJ, Sousa  et al (2011) Nanoparticle mediated delivery of pure P53 supercoiled plasmid DNA for gene therapy. J Control Release 156:212-222. doi:10.1016/j.jconrel.2011.08.007
15. Gumbleton M, Audus KL (2001) Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 90:1681-1698 (Pubitemid 33062590)
16. Guterstam P, Madani F, Hirose H et al (2009) Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta 1788:2509-2517. doi:10.1016/j.bbamem.2009.09.014
17. Hervé F, Ghinea N, Scherrmann J-M (2008) CNS delivery via adsorptive transcytosis. AAPS J 10:455-472. doi:10.1208/s12248-008-9055-2
18. Ho IA, Lam PY, Hui KM (2004) Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum Gene Ther 15:719-732. doi:10.1089/1043034041648372 (Pubitemid 39095245)
19. Izsvák Z, Ivics Z (2004) Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther 9:147-156. doi:10.1016/j.ymthe. 2003.11.009 (Pubitemid 38256540)
20. Ke W, Shao K, Huang R et al (2009) Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30:6976-6985. doi:10.1016/j.biomaterials.2009.08.049
21. Li G, Simon MJ, Cancel LM et al (2010) Permeability of endothelial and astrocyte cocultures: in vitro blood-brain barrier models for drug delivery studies. Ann Biomed Eng 38:2499-2511. doi:10.1007/s10439-010-0023-5
22. Lindberg S, Copolovici DM, Langel Ü (2011) Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Ther Deliv 2:71-82
23. Lindgren ME, Hällbrink MM, Elmquist AM, Langel Ü (2004) Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J 377:69-76. doi:10.1042/BJ20030760 (Pubitemid 38114433)
24. Mäe M, EL-Andaloussi S, Lundin P et al (2009) A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 134:221-227
25. Malhotra M, Prakash S (2011) Targeted drug delivery across blood-brain-barrier using cell penetrating peptides tagged nanoparticles. Curr Nanosci 7:81-93. doi:10.2174/157341311794480336
26. Naik P, Cucullo L (2012) In vitro blood-brain barrier models: current. J Pept Sci 101:1337-1354. doi:10.1002/jps
27. Omidi Y, Campbell L, Barar J et al (2003) Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 990:95-112. doi:10.1016/S0006-8993(03)03443-7 (Pubitemid 37247600)
28. Pardridge WM (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3:90-105. doi:10.1124/mi.3.2.90
29. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14. doi:10.1602/neurorx.2.1.3
30. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12:54-61. doi:10.1016/j.drudis.2006.10.013
31. Regberg J, Srimanee A, Langel Ü (2012) Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals 5:991-1007. doi:10.3390/ph5090991
32. Rousselle C, Smirnova M, Clair P et al (2001) Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 296:124-131 (Pubitemid 32015070)
33. Rousselle C, Clair P, Temsamani J, Scherrmann J-M (2002) Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target 10:309-315. doi:10.1080/10611860290031886 (Pubitemid 34746312)
34. Scholz C, Wagner E (2012) Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release 161:554-565. doi:10.1016/j.jconrel.2011.11.014
35. Stewart KM, Horton L, Kelley SO, Horton KL (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6:2242-2255. doi:10.1039/b719950c (Pubitemid 351863664)
36. Thomas FC, Taskar K, Rudraraju V et al (2010) Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 26:2486-2494. doi:10.1007/s11095-009-9964-5. Uptake
37. Torchilin VP, Levchenko TS, Rammohan R et al (2003) Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100:1972-1977 (Pubitemid 36254558)
38. Veiman K-L, Mäger I, Ezzat K et al (2013) PepFect14 peptide vector for efficient gene delivery in cell cultures. Mol Pharm 10:199-210. doi:10.1021/mp3003557
39. Watanabe T, Dohgu S, Takata F et al (2013) Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND.3, bEND.5 and mouse brain endothelial cell 4. Biol Pharm Bull 36:492-495
40. Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp 71:113-128
41. Xin H, Sha X, Jiang X et al (2012) Anti-glioblastoma efficacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 33:8167-8176. doi:10.1016/j.biomaterials.2012.07.046
42. Yuan W, Li G, Gil ES et al (2010) Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann Biomed Eng 38:1463-1472. doi:10.1007/s10439-010-9920-x